Despite our efforts to eliminate heterogeneity, some outcome indicators still exhibited high levels of heterogeneity, prompting us to interpret the results with cautions for clinical practice when involving in the effect of SXNI for CHD by decreasing the frequency and duration of angina, decreasing CRP, improving blood lipids (decrease TC, TGD and LDL) and thrombosis factors (e.g., decrease FIB, PV, HCT, and HS). This evidence concerns the gene CRP and angina pectoris.